BAYER AG
- Country
- π©πͺGermany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
A Study to Learn More About the Safety of Damoctocog-alfa-pegol When Used in Routine Medical Care in Korean Participants With Hemophilia A
- Conditions
- Interventions
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 600
- Registration Number
- NCT06222697
- Locations
- π°π·
Many Locations, Multiple Locations, Korea, Republic of
A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 8
- Registration Number
- NCT06221475
- Locations
- π³π±
ICON plc, Groningen, Netherlands
A Study to Learn if Elinzanetant Affects the Ability to Drive and Brain Function in Healthy Women
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 64
- Registration Number
- NCT06219902
- Locations
- π¨π¦
AltaSciences, Mount-Royal, Canada
First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Conditions
- Interventions
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 135
- Registration Number
- NCT06217822
- Locations
- π§πͺ
Institut Jules Bordet / Nuclear Medicine, Anderlecht, Belgium
π§πͺAZ Groeninge Campus Kennedylaan - Urology, Kortrijk, Belgium
π¨π¦Cross Cancer Institute, Edmonton, Alberta, Canada
An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1800
- Registration Number
- NCT06204302
- Locations
- πΊπΈ
Bayer, Whippany, New Jersey, United States
A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction
- Conditions
- Interventions
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 106
- Registration Number
- NCT06195930
- Locations
- πΊπΈ
Reid Physician Associates | Cardiology Department, Richmond, Indiana, United States
π¦π·Instituto de Cardiologia de Corrientes Juana F. Cabral | Corrientes, Argentina, Corrientes, Argentina
π΅π±Centrum Medyczne Zdrowa, Krakow, Poland
An Observational Study to Learn More About How Safe Rivaroxaban is And How Well it Works in Children With Congenital Heart Disease Who Had a Heart Surgery Called the Fontan Procedure
- Conditions
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 50
- Registration Number
- NCT06193863
- Locations
- π―π΅
Many Locations, Multiple Locations, Japan
A Study to Learn More About How Well BAY3018250 Works and How Safe it is for People With Proximal Deep Vein Thrombosis
- Conditions
- Interventions
- First Posted Date
- 2023-11-29
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 255
- Registration Number
- NCT06149520
- Locations
- π§πͺ
Universiteit Ziekenhuis Antwerpen | Thoraxheelkunde Afdeling, Antwerp, Belgium
π§πͺImelda - Vascular Surgery Dept, Bonheiden, Belgium
π§πͺZiekenhuis Oost-Limburg | Genk, Sint-Jan campus - Thoracic Vascular Surgery Department, Genk, Belgium
An Observational Study to Learn More About the Use of Vericiguat in Korean People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in Real-world Setting
- Conditions
- Interventions
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 3000
- Registration Number
- NCT06148935
- Locations
- π°π·
Many Locations, Multiple Locations, Korea, Republic of
A Study to Learn More About the Safety and the Blood Level of BAY1747846 Given as Injection Into the Vein at Increasing Single Doses in Chinese Healthy Male Participants
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 24
- Registration Number
- NCT06135181
- Locations
- π¨π³
Beijing Hospital, Beijing, China